Rupam Bhattacharyya

This study identifies a stress-lipid kinase axis in NEPC driven by PIKfyve, revealing a synthetic vulnerability between PIKfyve and FASN that can be exploited for therapeutic targeting.

This study shows that degrading p300/CBP in prostate cancer suppresses tumor growth more effectively than inhibiting their activity, highlighting their role in maintaining the active AR enhanceosome.

This study identifies PIKfyve as a targetable vulnerability in pancreatic cancer by showing its role in lipid metabolism and synthetic lethality with KRAS-MAPK inhibitors.

The paper develops TransPRECISE, a Bayesian network framework, to analyze pan-cancer patient and cell line interactomes, identifying pathway activities and drug sensitivities across multiple cancer types.

The paper develops a network-based method to predict drug sensitivity for cancer patients using cell line and omics data, identifying effective drug-patient matches.